Author: Ken Dropiewski

Viz.ai and Cleerly Partner on Heart Disease Evaluation Using Artificial Intelligence

New partnership delivers critical insights to more cardiovascular care teams to identify and define atherosclerosis earlier SAN FRANCISCO – September 4, 2024 — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and Cleerly, the company working to create a new standard of care for the diagnosis of heart […]

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024.

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

September 03, 2024 08:30 AM Eastern Daylight Time LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the […]

Renata Medical Announces First Patient to Receive Minima Growth Stent Following FDA Approval

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Renata Medical, a leader in innovative vascular solutions for young, growing patients, proudly announces a major milestone with the successful implantation of its Minima Growth Stent in the first patient following its recent FDA approval. “Today marks the beginning of something special” Post this “Today marks the […]

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action

—Largest randomized data set to date on bioadaptor, with a complex patient population of 2,400 compared to a DES— —Primary endpoint of target lesion failure (TLF) non-inferiority at twelve months was met with a low event rate for DynamX despite increased patient complexity— —Pre-specified landmark analysis shows statistically significant reduction […]

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society’s HRX Congress

ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be prominently featured during the upcoming HRX digital health conference taking place September 5-7, 2024, in Atlanta, Georgia.

Vasa Therapeutics Announces Initiation of Phase 1 First-in-Human Clinical Trial of VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction

Vasa Therapeutics granted MHRA Clinical Trial Authorization (CTA) for VS-041 for the treatment of heart failure with preserved ejection fraction (HFpEF) Company’s seed funding extended to $11M ENCINITAS, Calif. and WROCLAW, Poland, Sept. 3, 2024 /PRNewswire/ — Vasa Therapeutics (“Vasa”),…